Presentatie - vzw farmaka asbl

Anti-aggregantia - ASA
Gami P. Secondary prevention of ischaemic cardiac events. Clinical Evidence 2007.
Design N/n Population Sd Interventions Outcomes Results
MA (search N=6, n=6300 -Cardiovas -Low dose aspirin All cause OR= 0.82 (95%CI 0.70 to 0.99)
date 2002)
cular
disease
(≤325 mg)
-placebo
mortality
MI OR= 0.70 (95%CI 0.60 to 0.80)
Gastrointestinal
haemorrhage
OR= 2.5 (95% CI 1.4 to 4.7) in favour of
placebo
MA (search
1997)
N=16, n=
55462
3 y -Aspirin (all doses)
-Control
Intracranial
haemorrhage
Increased in 0.1%
MA (search
2002)
MA (search
1999)
N=25,
n=287616
N=19, n=
165.616
N=3,
n=2224)
Indirect comparison
of aspirin doses
Overall
haemorrhage
-325 mg 9.9% (8.4 to 11.4%)
-Low dose aspirin
(≤325 mg)
-Control
-Aspirin (>325 mg)
-Control
Intracranial
haemorrhage
Increased risk with higher dose
Event rates:
No significant differences (event rate
with aspirin: 0.3% (95%CI 0.2 to .04%))
Increased risk with aspirin (event rate
with aspirin: 1.1% (95%CI 0.7% to
1.5%))
Increased risk with higher dose
Event rates:
-Indirect comparison
of aspirin doses:
Gastrointestinal
haemorrhage
N=5,
-325 mg 2.5% (95%CI 1.8% to 3.1%)
N=24,
-Aspirin
Gastrointestinal
n=65987
-Control
haemorrhage
-Mixed
primary
and
secondary
prevention
OR= 1.68 (95% CI 1.51 to 1.88) in
favour of placebo
No definite variation in risk between
doses